about
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesEarly versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.Melphalan and its role in the management of patients with multiple myeloma.Insights into defibrotide: an updated review.High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomibHow to treat elderly patients with multiple myeloma: combination of therapy or sequencing.Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Management of older patients with multiple myeloma.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.Novel investigational drugs active as single agents in multiple myeloma.Nuances in the Management of Older People With Multiple Myeloma.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.Emerging drugs and combinations to treat multiple myeloma.Autologous transplantation and maintenance therapy in multiple myeloma.Management of disease- and treatment-related complications in patients with multiple myeloma.Towards a new standard of care for patients with myeloma?Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report.Autologous transplant for myeloma: when the old meets the new.Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Plasma cell leukemia: update on biology and therapy.
P50
Q33378895-8CBAB637-682C-4CDB-9DD0-252C43EA48B7Q33695919-C2682A4F-09C3-41A6-BE4C-B2737069DE9DQ34272540-1D579E8E-D919-4C62-B1C4-E709025DD831Q35685454-AFD409E3-718A-4706-8710-D57AE0A1BE61Q36879132-A8EC1EA5-F38C-4749-8F0C-AB1DFF179351Q37489891-C98AFEBE-671F-4EF9-8870-A08DFEBE9D08Q37552101-7A602B4F-F063-4BDD-9DEC-4931D86201CCQ37653286-1F073854-3B7F-4B6F-BF47-71FF6E8A544DQ37701511-AC1F954F-61EF-47A4-91E3-DFB3EEE0FB4FQ37835951-12AA1E4B-FED6-4A35-8F02-20C49C44DA93Q38031989-3EC657C4-264A-42A2-BDF3-A9AE29271F36Q38130301-2F238F7B-3D69-4C2B-B857-30CD69224CDFQ38205856-DCC6A979-C415-4112-901A-DB2DD045287FQ38218209-EBFAF4B8-24B3-4425-A1B5-139D903BD084Q38375463-8D1A2CAB-E640-4C00-9E98-68C7DF391A98Q38609472-28AD7FBB-8CF2-4AA1-ADE0-CBC3EDB08910Q38657175-BC0A3B24-634E-4F1E-858E-DA5FFD6CB574Q38690290-C63E5B95-B050-40A1-84C7-7594C8CF5F6FQ38796491-C00368E6-2407-4D6A-AF22-1F32527931E3Q38815405-EFEF80C1-E6F9-426E-988F-528B13C83D46Q38973358-2C64713E-FE8C-4282-97AA-9103E6069FE3Q39070193-BD392F47-5BDB-43F1-A9FF-AD6F6F6BF0D8Q39071875-07EC4558-EC0E-4D03-B7D6-D5814637CB7FQ39423090-8A26C511-6813-4F76-B58B-D02D81929404Q40404841-3387CEC5-AB5F-4088-BBD8-9DBF89A7643CQ40454277-4001F630-8FBD-4EB9-BEF9-B6C15E3E6D3DQ40899348-45EAA8D4-522C-45E0-96BA-D5CD3DFF7035Q41694198-DFB8338F-63E4-4831-A2BA-BAD4DA1F27A0Q41756278-60195BEC-8114-4379-9D2A-4E6062EE882FQ43063702-1299D800-76AE-4F6F-99B8-35861AE234D5Q43255805-B80EDBAA-F289-4759-B954-EB624656A118Q45192496-6B2D9B0A-5375-41D6-97C6-3750EE618737Q46046656-44D93576-7FDD-413F-994A-94AA3B6CF46DQ46573449-2E395C0B-2310-4091-8950-74508C29A6BDQ46880822-106F9DF6-6716-40AD-A025-55A09DE971D4Q47153254-A6FEA0CA-0C31-4C89-B963-664AC877D5FEQ48360689-6FA68056-19C4-48E0-B1E1-E1E7A19EEAE5Q49375952-6943A1D4-0CC0-48FD-AFB1-6065B927AA81Q52801394-E0E33A1F-E52A-4FF8-8776-77F71E59495AQ52838137-2C2E4A0B-2280-4013-AC29-43C0E1A3AE13
P50
description
investigador
@es
researcher
@en
name
Francesca Gay
@en
Francesca Gay
@nl
type
label
Francesca Gay
@en
Francesca Gay
@nl
prefLabel
Francesca Gay
@en
Francesca Gay
@nl
P31
P496
0000-0002-8619-412X